Author:
Nelson Peter T.,Lee Edward B.,Cykowski Matthew D.,Alafuzoff Irina,Arfanakis Konstantinos,Attems Johannes,Brayne Carol,Corrada Maria M.,Dugger Brittany N.,Flanagan Margaret E.,Ghetti Bernardino,Grinberg Lea T.,Grossman Murray,Grothe Michel J.,Halliday Glenda M.,Hasegawa Masato,Hokkanen Suvi R. K.,Hunter Sally,Jellinger Kurt,Kawas Claudia H.,Keene C. Dirk,Kouri Naomi,Kovacs Gabor G.,Leverenz James B.,Latimer Caitlin S.,Mackenzie Ian R.,Mao Qinwen,McAleese Kirsty E.,Merrick Richard,Montine Thomas J.,Murray Melissa E.,Myllykangas Liisa,Nag Sukriti,Neltner Janna H.,Newell Kathy L.,Rissman Robert A.,Saito Yuko,Sajjadi S. Ahmad,Schwetye Katherine E.,Teich Andrew F.,Thal Dietmar R.,Tomé Sandra O.,Troncoso Juan C.,Wang Shih-Hsiu J.,White Charles L.,Wisniewski Thomas,Yang Hyun-Sik,Schneider Julie A.,Dickson Dennis W.,Neumann Manuela
Abstract
AbstractAn international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer’s disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience.
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology (clinical),Pathology and Forensic Medicine